Moreover , in the last few week Dtwoother trial involve another Genentech cancer drug , Avastin , BE stop early after that drug , already approve for colon cancer , BE show to work for lung cancer and breast cancer as well .
Indeed , the company , base in South San Francisco , Calif. , say Monday that with demand for Avastin and Herceptin expect to grow Rfastthan expect , it would have to review its plan to make sure it have enough manufacture capacity .
Genentech say that 34,000 women a year get adjuvant treatment for HER2-positive breast 
